COSA 2016November 15 - 17, 2016 Gold Coast Convention and Exhibition Centre

Breakfast Sessions

Tuesday 14th November

Physical activity and cancer

Time: 07:00 - 8:15am 

Content: In this interactive breakfast session invited international speaker, Professor Melinda Irwin from Yale School of Public Health, will discuss current and future opportunities and challenges in physical activity and cancer research and clinical care. Prof Irwin is a prominent leader in the field of physical activity and cancer risk and mortality. Her research over the past 15 years has focused on randomized trials of exercise and weight loss on biological markers, treatment side effects and quality of life in cancer patients and survivors.

Speaker: Melinda Irwin, Yale School of Public Health, 

Breakfast is included with this session, however, you must indicate your attendance by selecting the 'Physical activity and cancer' breakfast symposium on your online profile.

This breakfast session is supported by

 COSA logo blue on white

How the management of breakthrough cancer pain is evolving

Time: 07:00 - 08:15am

Content: This breakfast symposium will provide attendees with insights into breakthrough cancer pain: the definition of breakthrough cancer pain, how its management is evolving and what this means for the doctor, the palliative care team and the patient. Professor Richard Chye, Palliative Care specialist at St Vincent’s Hospital, Sydney, will share his knowledge relating to the management of breakthrough cancer pain. A patient will also discuss the impact of effective breakthrough cancer pain management on his quality of life. There will be time for questions and discussion.

Speaker: Professor Ricahrd Chye Director, Sacred Heart Supportive & Palliative Care St Vincent’s Hospital Sydney, NSW

Breakfast is included with this session, however, you must indicate your attendance by selecting the 'How the management of breakthrough cancer pain is evolving' breakfast symposium on your online profile.

This breakfast session is supported by

menarini

Managing Afinitor-associated stomatitis in patients with hormone-receptor positive metastatic breast cancer

Time: 07:00 - 08:15am

Content: This breakfast symposium will give attendees insights into the practical aspects of proactively managing everolimus-induced stomatitis In the recently reported SWISH clinical trial, prophylactic use of a dexamethasone solution as a mouthwash four times daily for the first 8 weeks of treatment significantly reduced the incidence of everolimus-induced stomatitis1. In the light of the SWISH trial outcome, this session will discuss the practicalities of managing everolimus-associated stomatitis in Australia with two real-world perspectives. Dr Lina Pugliano will review the SWISH trial data and then discuss her experiences and give her insights into prophylactically managing everolimus-related stomatitis. Pharmacist Obaid Fazli will outline different approaches to supplying everolimus patients with steroidal mouthwash that are currently being practised in Australia, highlighting the practical benefits and limits of these.

1Rugo, HS, J Clin Oncol 34, 2016 (suppl; abstr 525)

Speakers: 
Dr Lina Pugliano, Medical Oncologist Northern Cancer Institute (NCI) St Leonards, Sydney, NSW 
SWISH trial recap: using prophylactic steroidal mouthwash to control everolimus-associated stomatitis 

Obaid Fazli, Assistant Deputy Director and Senior Oncology Pharmacist, Monash Health-Moorabbin Pharmacy Department, Melbourne, Victoria 
Putting SWISH into practice: adapting SWISH to the Australian setting 

Breakfast is included with this session, however, you must indicate your attendance by selecting the 'Managing Afinitor-associated stomatitis in patients with hormone-receptor positive metastatic breast cancer' breakfast symposium on your online profile.

This breakfast session is supported by

Novatis

 



Cancer Pain Symposium

Time: 07:00 - 8:15am

Content: This symposium will be an update on the current management of cancer pain, exploring the current basis of treatment and its limitations and discussing alternative management options in common practice in the U.S.A and Europe. The first session by Professor Paul Glare will discuss Opiate medication, its development as the mainstay of cancer pain management and the W.H.O model. Despite this development, opioids have limited efficacy and the model of cancer pain management has not changed despite the enormous progress seen in oncology treatment. Furthermore, with oncological advances the profile of the patient during or post cancer treatment specifically has changed drastically in the lifespan of the W.H.O model. Additionally, the landscape of opiate misuse has changed drastically with Australia experiencing an “opioid epidemic”. Chronic non-cancer pain management has altered in this time to carefully protocolised opioid therapy. Cancer pain management is still considered as a separate entity to non-cancer pain management, however, considerable overlap exists with the oncology patient experiencing multiple non oncological morbidities. Many further similarities exist between these populations and therefore chronic non-cancer pain management can be adapted to provide multidisciplinary, efficacious and non opioid based pain solutions in patients with cancer.

The second session from Dr Tim Hucker will discuss non opioid medication and interventional options for cancer pain management. europathic pain is prevalent in cancer, either from the cancer itself or its treatment and throughout the cancer journey. Even in survivorship, neuropathic pain is common and persistent. The limitation of efficacy in opiate management of neuropathic pain will be highlighted. Despite being part of cancer pain management guidelines and contrary to other countries, interventional pain options are infrequently considered. There are a wide variety of pain syndromes in the cancer patient and interventional options exist in many situations. The careful application of interventional techniques in this population will aid efficacy and also assist in limiting opiate related side effects and wider opiate burden.

Chair: Tim Hucker

Speakers: 
Tim Hucker
Paul Glare

Breakfast is included with this session, however, you must indicate your attendance by selecting the 'Cancer Pain Symposium' breakfast symposium on your online profile.

This breakfast session is supported by 

art logo cmyk bl eps copy

Wednesday 15th November

Not just a tick box: How engaging with consumers can add value to your research

Time: 07:00 - 08:45

Content: Many researchers and research organisations recognise the value of engaging with consumers with the consistent message being that people who have a personal experience of cancer bring a unique perspective and a wealth of diversity, knowledge, and capabilities to research and health initiatives. In addition, funding bodies almost always insist on researchers demonstrating this perspective has been sought for applications to be considered favourably. However, some hesitation still exists and connecting effectively is often easier said than done. Can a lay person really understand research concepts and provide meaningful input? This session will provide examples of working partnerships and what it takes for individual researchers, research organisations, and consumers to work collaboratively to bring better health outcomes for people affected by cancer.

Speakers: TBC

Breakfast is included with this session, however, you must indicate your attendance by selecting the 'Consumer involvement in research' breakfast symposium on your online profile.

This breakfast session is supported by 

COSA logo blue on white ANZBCTG

Clinician involvement in cancer medicines access decisions

Time: 07:00 - 08:45

Content: Governments throughout the world are exploring ways by which affordable access to innovative cancer medicines can be expedited. A number of years ago Canada implemented a specialised pan-Canadian Oncology Drug Review (pCODR), outside of the regular reimbursement process. Bill Evans is an oncologist and former member of the pCODR Expert Review Committee (pERC). This symposium will be an opportunity to examine some of the challenges for access to medicines in Australia, and understand how clinicians can play a role in supporting timely and affordable cancer treatment.

Speakers:

David Pullar, Co-Chair of Medicines Australia Oncology Industry Taskforce (moderator)

Dr Bill Evans, former member of Pan-Canadian Oncology Drugs Review
Dr Deme Karikios, Medical Oncology Group of Australia
Liz de Somer - Medicines Australia Director of Policy and Advocacy

Breakfast is included with this session, however, you must indicate your attendance by selecting the 'Clinician involvement in cancer medicines access decisions' breakfast symposium on your online profile.

This breakfast session is sponsored by 

MA

 

Advances in the neoadjuvant treatment of HER2-positive breast cancer

Time: 07:00 - 8:45am

Content: Neoadjuvant treatment of breast cancer is becoming an integral part of modern multidisciplinary cancer management. Join us for breakfast with international expert Dr Laura Esserman, as she covers the clinical evidence and more practical aspects of neoadjuvant treatment in HER2-positive breast cancer. Following this, a multidisciplinary panel will discuss how this evidence translates in to clinical practice in Australia, now and in to the future.

Chair: Richard de Boer
Speakers:
Bruce Mann – From diagnosis to neoadjuvant treatment – tips for ensuring a smooth ride
Laura Esserman – Neoadjuvant treatment as a platform for translational research
Nicholas Zdendowski – The current and future scenario in Australia – An oncologist’s perspective
Panel discussion and audience Q&A

Breakfast is included with this session, however, you must indicate your attendance by selecting the 'Advances in the neoadjuvant treatment of HER2-positive breast cancer' symposium on your online profile.

This breakfast session is supported by

Roche logo

 

Thursday 17th November

Reflection & Writing in Medicine: Why It Matters, How to Write & Where to Publish with keynote speaker Ranjana Srivastava

Time: 07:00 - 08:45

Content: In this session, Dr. Ranjana Srivastava, oncologist, award-winning author and columnist for The Guardian, explores the role of reflection and writing in medicine and its importance in improving the self and the doctor-patient relationship.

In tracking her own journey, she recounts the satisfactions and the challenges of writing and discusses some of the pitfalls and ethical dilemmas of writing about patients and doctors. Based on her experiences in print, radio and television, she emphasises the value of demystifying medicine to the public and provides tips on doing so while maintaining a busy professional career.
This is an interactive session where audience questions are most welcome. Signed books will be available.

Speaker: Ranjana Srivastava

Breakfast is included with this session, however, you must indicate your attendance by selecting the ''Writing and reflection with keynote speaker Ranjana Srivastava' breakfast symposium on your online profile.

This breakfast session is supported by

COSA logo blue on white

 

Scalp Cooling: Why It’s Cool and How to Keep Your Cool

Time: 07:00 - 08:45 

Content:
This breakfast session will address the latest evidence regarding scalp cooling and the work being undertaken by the CHILL group (www.scalpcooling.org). It will provide information as to why scalp cooling should be available not only for women undergoing breast cancer chemotherapy but also for other cancer types especially prostate. A key focus will include managing patient throughput (chair-time) while offering scalp cooling. The session will discuss practical tips for maximising hair retention with the latest cap innovation and information on cooling times to optimise hair retention. The session will also cover the important and emerging role hairdressers can play in helping patients manage their hair during treatment.

The session will conclude with a panel discussion on scalp cooling experiences with ample time for questions from the floor.

Speakers:
Professor Fran Boyle, Mater Private Hospital, Sydney (Chairperson)
Vicki Durston, Breast Cancer Services Coordinator, Cabrini Health, Melbourne
Mandy O’Reilly, Patient Support and Education Officer
Panellists in addition to the speakers will include:
Dr Yoland Antill, Oncologist, Cabrini Health, Melbourne
Nursing Support (TBC), Patricia Ritchie Centre Mater Private Hospital, Sydney

Breakfast is included with this session, however, you must indicate your attendance by selecting the 'Scalp Cooling' breakfast symposium on your online profile.

This breakfast session is sponsored by  

Regional health Care Group paxman logo 1col low